Montelukast Accord (Montelukast Sodium)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth muscle and inflammatory cells. By preventing leukotrienes from binding, it reduces bronchoconstriction, mucus production, vascular leakage and eosinophilic inflammation, which together improve breathing and lessen allergic symptoms.

The specific dose of Montelukast Accord is determined by the prescribing healthcare professional based on the patient’s age, condition severity and concomitant therapies. Clinicians follow approved dosing guidelines, and patients should follow the exact regimen written on their prescription.

Safety data for Montelukast during pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss them with the patient. Women who are pregnant, planning pregnancy, or breastfeeding should consult their physician before starting therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or antihistamines for asthma and allergic rhinitis. While inhaled steroids directly reduce airway inflammation, montelukast provides convenient once‑daily dosing and is especially useful for patients with exercise‑induced symptoms or those who prefer oral therapy.

Montelukast Accord should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Montelukast Accord is taken orally, usually once daily in the evening. It can be swallowed with water and may be taken with or without food, according to the prescribing clinician’s instructions.

Serious risks include neuropsychiatric events such as depression, mood changes or suicidal thoughts, as well as severe allergic reactions like rash, angioedema or anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Accord should be avoided in individuals with known hypersensitivity to montelukast sodium or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment, and it should only be used under medical supervision in such cases.